EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma
Abstract T-cell lymphoma (TCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that is associated with a poor prognosis. Although HDAC inhibitors have been approved for TCL treatment for several years, their expected therapeutic efficacy remains unmet in some patients. In this study, we discovered t...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-07-01
|
| Series: | Cell Death and Disease |
| Online Access: | https://doi.org/10.1038/s41419-025-07775-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|